2008 Press Releases
TSX:V - IXS
NASD OTC:BB: IXSBF
April 15, 2008
InNexus Biotechnology to Present Data at AACR -- New DXL625 (CD20) Data Demonstrates Superiority Versus Competing CD20 Antibodies --
BRITISH COLUMBIA, Canada-15 April 2008-InNexus Biotechnology Inc. (OTCBB: IXSBF)(TSX VENTURE: IXS), (http://www.ixsbio.com), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL™),announced today the company has presented new in vivo proof of principle data at the American Association for Cancer Research (AACR) Annual Meeting 2008 in San Diego, California.
“Through the use of a novel in vivo model for B-cell depletion, also developed by InNexus scientists, we have obtained evidence that DXL625 is superior to a competing commercial anti-CD20 in reducing numbers of circulating B-cells. The animal model revealed no increased immunogenicity or toxicity associated with administration of DXL625 versus the commercial anti-CD20,” said Dr. Thomas Kindt, InNexus Biotechnology’s Chief Scientific Officer. “These recent data confirm in vitro results showing DXL625 to be a more potent inducer of B-cell apoptosis and furnish convincing proof of principle demonstrating the superiority of DXL625. The agreement of data from several different types of experimental tests establishes our point concerning the value of DXL™ technology to enhance antibody activity and potency.”
Commenting on the latest achievement of InNexus, Jeff Morhet, Chairman and Chief Executive Officer said, “Establishing this in vivo proof of principle data is another significant milestone in our preclinical development timeline. We’re proud to be presenting this data to our peers at the AACR Annual Meeting 2008 and we will continue to drive forward in our development of DXL625. We are preparing for an upcoming pre-IND meeting with the FDA and our next preclinical milestone is the kickoff of an extensive primate study later this year.”
The data presented at the AACR Annual Meeting 2008 on April 15, 2008 is now available for download at the InNexus website, www.ixsbio.com\AACR2008.html
About AACR Annual Meetings
Each year the AACR holds an annual conference which serves as a forum for cancer researchers working in all subdisciplines of the cancer field: the AACR Annual Meeting. More than 15,000 participants from 60 countries gather to discuss over 6,000 abstracts and to hear more than 250 invited presentations on new and significant discoveries in basic, clinical, and translational cancer research. Scientific award lectures, grant writing workshops, networking events, and educational sessions round out this comprehensive program.
About InNexus
InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL™ antibodies utilize unique, novel and patented methods and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of The Mayo Clinic and has its own in–house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward–looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements.
Contact:
Jeff Morhet, Chairman & Chief Executive Officer
Dr. Thomas Kindt, Chief Scientific Officer
InNexus Biotechnology Inc.
480-862-7500
www.ixsbio.com
